Lantheus
LNTH
Hutchmed (China)
HCM
Workday
WDAY
DexCom
DXCM
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
HOTH Hoth Therapeutics
- 0.9444
- -0.0056-0.59%
Close Feb 26 16:00 ET
12.42MMarket Cap-0.74P/E (TTM)
0.9820High0.9000Low109.85KVolume0.9422Open0.9500Pre Close104.37KTurnover0.84%Turnover RatioLossP/E (Static)13.15MShares3.800052wk High1.66P/B12.35MFloat Cap0.580052wk Low--Dividend TTM13.08MShs Float347.0000Historical High--Div YieldTTM8.63%Amplitude0.5800Historical Low0.9500Avg Price1Lot Size
About Hoth Therapeutics Company
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Company Profile
SymbolHOTH
Company NameHoth Therapeutics
Listing DateFeb 15, 2019
Issue Price5.60
Founded2017
CEOMr. Robb Knie
MarketNASDAQ
Employees6
Fiscal Year Ends12-31
Address1177 Avenue of the Americas,5th floor,Suite 5066
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036
Phone1-646-756-2997
Company Executives
- Name
- Position
- Salary
- Robb Knie
- Chairman of the Board, President and Chief Executive Officer
- 868.82K
- David S. Briones
- Chief Financial Officer and Principal Accounting Officer
- --
- Graig Springer
- Independent Director
- 65.21K
- Dr. Jeff Pavell, M.D.
- Independent Director
- 65.21K
- Wayne D. Linsley
- Independent Director
- 65.21K
- David B. Sarnoff
- Independent Director
- 65.21K